In conclusion, our results demonstrate that oxaliplatin significantly inhibits CRC cell growth and that this inhibition may be associated with simultaneous increases in CYP2S1 and p53 expression, leading to downregulation of Wnt/β-catenin signaling (Fig. 6). Here, TP53 is linked to colorectal carcinoma.